Cancer Research UK, by way of its commercial division known as Cancer Research Technology, will collaborate with Abcodia on new blood tests designed to spot cancers at very early stages.
Early detection boosts colon cancer survival rates. The Yonsei University College of Medicine in Seoul, South Korea, and Genomictree believe they can accomplish this goal, thanks to a noninvasive biomarker blood test that appears to be highly accurate based on initial clinical work.
CHICAGO--The showdown between Bristol-Myers Squibb ($BMY) and Merck ($MRK) over a new PD-1 approach to spurring an immune response to cancer didn't disappoint.
Researchers in California say they believe circulating tumor cells, captured and analyzed by new technology, could function as a 'liquid biopsy." If further studies confirm the effectiveness of the NanoVelcro Chip, prostate cancer could be more easily tracked over time to provide personalized treatments.
Swedish researchers believe that screening for the biomarker, perhaps with a simple urine test, could allow for more targeted treatment at an earlier enough stage to give patients a fighting chance, or at least indentify realistic options.
Just a year or two ago, analysts and investors were in a frenzy over the frantic race to develop a new set of hepatitis C drugs that promised to change the standard of care. Now, as the leaders in that race approach the first round of likely marketing approvals, a new R&D competition has grabbed analysts' feverish attention as the next big thing in biopharma. And the leading players in this field may once again be betting on a mega-blockbuster payoff.
Diagnosing the difference between pancreatic cancer and chronic pancreatitis is difficult because both conditions produce similar symptoms such as inflammation. But Mayo Clinic scientists say they've discovered a biomarker that will help make the job much easier down the line.
MIT researchers may have discovered a key protein involved in cell death--one that could help kill remaining cancer cells after chemotherapy.
Bristol-Myers Squibb has emerged, at least temporarily, as the leader in a race to develop the first new PD-1 drug to fight cancer.
Determined to prove to investors that AstraZeneca has a late-stage game plan that can rescue the pharma company from a lengthy losing streak, the company today spotlighted plans to speed up the Phase III development timeline on three key cancer drugs.